Abstract

Kininogens, the precursor proteins of the vasoactive kinins, bind specifically, reversibly, and saturably to platelets, neutrophils, and endothelial cells. Two domains of the kininogens expose major cell binding sites: domain D3 that is shared by H- and L-kininogen and domain D5H that is exclusively present in H-kininogen. Previously we have mapped the kininogen cell binding sites to 27 residues of D3 ("LDC27") and 20 residues of D5H ("HKH20"", respectively (Herwald, H., Hasan, A. A. K., Godovac-Zimmermann, J., Schmaier, A. H., and Müller-Esterl, W. (1995) J. Biol. Chem. 270, 14634-14642; Hasan, A. A. K., Cines, D. B., Herwald, H., Schmaier, A. H., and Müller-Esterl, W. (1995) J. Biol. Chem. 270, 19256-19261). The corresponding kininogen acceptor site(s) exposed by the cell surfaces are still poorly defined. Using a non-ionic detergent, Nonidet P-40, we have been able to solubilize kininogen binding sites from an endothelial cell line, EA.hy926, in their functionally active form. Affinity chromatography of the solubilized kininogen binding sites on HKH20, a synthetic peptide representing the D5H cell binding site, allowed us to isolate a 33-kDa protein ("p33") that binds specifically and reversibly to H-kininogen with a KD (apparent dissociation constant) of 9 +/- 2 nM. Preparative SDS electrophoresis followed by NH2-terminal amino acid sequence analysis identified the kininogen-binding protein p33 as the gC1q receptor ("gC1qR"), an extrinsic membrane protein that interacts with the globular domains of the complement component C1q. The purified p33 binds C1q with moderate affinity, KD = 240 +/- 10 nM. Recombinant expression of the corresponding cDNA in Escherichia coli demonstrated that p33 binds H-kininogen, but not L-kininogen. Peptide HKH20 but not peptide LDC27 inhibited binding of H-kininogen to the recombinant p33 in a concentration-dependent manner, indicating that H-kininogen binds to p33 via domain D5H. Recombinant p33 efficiently inhibited the binding of H-kininogen to EA.hy926 cells. Factor XII, but not prekallikrein, competed with H-kininogen binding to p33. These findings suggest that an endothelial binding protein mediates the assembly of critical components of the kinin-generating pathway on the surface of endothelial cells, thereby linking the early events of kinin formation and complement activation.

Highlights

  • Kininogens, the precursor proteins of the vasoactive kinins, bind reversibly, and saturably to platelets, neutrophils, and endothelial cells

  • The failure of the peptide HKH20 to completely block the binding of biotinylated H-kininogen reflects the fact that the H-kininogen binding to the endothelial cell is in part mediated by domain D3 [13]

  • Peptide KHG20 showed no inhibitory effect, indicating that the high affinity of peptide HKH20 for p33 is sequence-specific and not solely due to an accumulation of positively charged side chains. These results are in good agreement with the data obtained from intact endothelial cells where HKH20 was by far the most efficient inhibitor whereas GKE19 and HNL21 were by a factor of 103 less effective [12]

Read more

Summary

The abbreviations used are

H-kininogen, high molecular weight kininogen; L-kininogen, low molecular weight kininogen; BIA, biospecific interaction analysis; D, kininogen domain; ELISA, enzyme-linked immunosorbent assay; gC1qR, receptor for globular domains of C1q; HPLC, high performance liquid chromatography; HUVEC, human umbilical vein endothelial cell; MBP, maltose-binding protein; PAGE, polyacrylamide gel electrophoresis; PBS, phosphate-buffered saline; CHAPS, 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonic acid; ABTS, diammonium 2,2Ј-azino-bis(3-ethyl-2,3-dihydrobenzthiazoline-6-sulfonate). Subsequent liberation of kinins on their surfaces may represent a general mechanism by which systemically available prohormones are recruited by their target cells followed by the circumscribed release of their cognate hormones [12] By virtue of this mechanism short-lived peptide hormones such as kinins are locally released at or close to their site of action. The corresponding peptide, HKH20, bound reversibly, and saturably to endothelial cells with an apparent KD (apparent dissociation constant) of 230 nM. In line with these findings the intermediate domain D4, which separates D3 and D5H in H-kininogen, contributes to the optimum binding of kininogen to endothelial cells [17]. Our data suggest that endothelial cells expose a binding protein that serves as a promiscuous docking structure for the plasma proteins, H-kininogen and C1q

EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
Methods
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call